A Rare B-Myeloid Conversion of Follicular Lymphoma into Clonally Related Acute Myeloid Leukemia: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36983884/
Follicular lymphoma (FL) is a highly prevalent indolent lymphoma, and the risk of histological transformation is approximately 2-3% per year. Transformation of FL generally occurs in the same lineage (B...
Summary: B-myeloid conversion of follicular lymphoma into clonally related AML is extremely rare. Coactivation of NF-κB and Notch signaling is sufficient to lead B-myeloid conversion. Patients with this transformation are associated with an aggressive clinical course and poor prognosis. The m7-FLIPI can improve the prognosis of patients with...
A Rare Case of Primary Breast Diffuse Large B-cell Lymphoma in an Acquired Immunodeficiency Syndrome Patient - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37050986/
Primary breast lymphoma (PBL) is not a commonly seen subtype of breast cancer, and it is also unusual for an extranodal variant of diffuse large B-cell lymphomas (DLBCLs) to appear...
Conclusions/Relevance: This case demonstrated that painful breast and axillary masses in an acquired immunodeficiency syndrome (AIDS) patient can grow quickly, be misdiagnosed, and require an expedient workup, as extranodal DLBCL can be a debilitating disease.
Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37015002/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Pre-ASCT MTV and SUVmax appear to be of greater predictive value than the degree of response. Potential application may exist for PET-directed management of R/R DLBCL patients.
The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
Source : https://www.frontiersin.org/articles/10.3389/fonc.2023.1130617/full
Measurable residual disease (MRD) status in chronic lymphocytic leukemia (CLL), assessed on and after treatment, correlates with increased progression-free and overall survival benefit. More recently, MRD assessment has been included...
Relevance: We explore the assessment and reporting of MRD (including novel techniques) and the challenges of standardization and provide a comprehensive review of the relevance and adequacy of MRD as a clinical trial endpoint. We further discuss the impact that MRD data have on clinical decision-making and how it can influence a...
Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36902559/
A fixed duration of venetoclax-rituximab (VenR) resulted in a significant benefit of both PFS and in the attainment of an undetectable minimal residual disease (uMRD) compared with bendamustine-rituximab in relapsed/refractory...
Conclusion: To the best of our knowledge, in this real-life study we have assessed for the first time in general practice the responses to a fixed dose VenR in R/R CLL patients by US. Ultrasound detected echostructural changes consistent with nodal and splenic CR in a substantial proportion of patients, along with the achievement of uMRD. US...